Pharmacokinetics and pharmacodynamics of an innovative psychedelic N,N-dimethyltryptamine/harmine formulation in healthy participants: a randomized controlled trial
International Journal of Neuropsychopharmacology · 28.12.2024 · 28 (1)
DOI: 10.1093/ijnp/pyaf001 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift International Journal of Neuropsychopharmacology, online erschienen am 08.01.2025. Verfasst von Michael J Mueller und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Adult Psychiatry and Psychotherapy, Psychiatric University Clinic Zurich and University of Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Hallucinogens, Harmine, N,N-Dimethyltryptamine. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fabian Hediger, SNSF Swiss National Science Foundation, Bioentrepreneur Fellowship UZH.
Abstract (Originalsprache)
Background
Recent interest in the clinical use of psychedelics has highlighted plant-derived medicines like ayahuasca showing rapid-acting and sustainable therapeutic effects in various psychiatric conditions. This traditional Amazonian plant decoction contains N,N-dimethyltryptamine (DMT) and β-carboline alkaloids such as harmine. However, its use is often accompanied by distressing effects like nausea, vomiting, and intense hallucinations, possibly due to complex pharmacokinetic/pharmacodynamic (PK-PD) interactions and lack of dose standardization.
Methods
This study addresses these limitations by testing a novel pharmaceutical formulation containing pure forms of DMT and harmine in a double-blind, randomized, placebo-controlled trial with 31 healthy male volunteers. We evaluated PK-PD by monitoring drug and metabolite plasma levels, subjective effects, adverse events, and cardiovascular parameters. Each participant received 3 randomized treatments: (1) 100 mg buccal harmine with 100 mg intranasal DMT, (2) 100 mg buccal harmine with intranasal placebo, and (3) full placebo, using a repeated-intermittent dosing scheme, such that 10 mg of DMT (or placebo) was administered every 15 minutes.
Results
N,N-dimethyltryptamine produced consistent PK profiles with Cmax values of 22.1 ng/mL and acute drug effects resembling the psychological effects of ayahuasca with a duration of 2–3 hours. Likewise, buccal harmine produced sustained-release PK profiles with Cmax values of 32.5 ng/mL but lacked distinguishable subjective effects compared to placebo. All drug conditions were safe and well tolerated, indicating the formulation’s suitability for clinical applications.
Conclusions
This study underscores the potential of a patient-oriented pharmaceutical formulation of DMT and harmine to reduce risks and improve therapeutic outcomes in treating mental health disorders. Clinical trial registration number Neurodynamics of prosocial emotional processing following serotonergic stimulation with N,N-dimethyltryptamine (DMT) and harmine in healthy subjects (NCT04716335) https://clinicaltrials.gov/ct2/show/NCT04716335
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Adult Psychiatry and Psychotherapy, Psychiatric University Clinic Zurich and University of Zurich, Zurich, Switzerland.
- Department of Health Science & Technology, ETH Zurich, Zurich, Switzerland.
- Neuroscience Center Zurich, University of Zurich and Swiss Federal Institute of Technology Zurich, Zurich, Switzerland.
- Department of Psychology, University of Zurich, Zurich, Switzerland.
- Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.
- Department of Forensic Pharmacology and Toxicology, Zurich Institute of Forensic Medicine, University of Zurich, Zurich, Switzerland.
ORCID-Profile: Michael J Mueller, Jonas Kost, Boris B Quednow, Milan Scheidegger
Förderung
- Fabian Hediger
- SNSF Swiss National Science Foundation
- Bioentrepreneur Fellowship UZH
- Forschungskredit PostDoc UZH
- BIAL Foundation
- Reconnect Foundation
Zitieren
APA
Mueller, M. J., Aicher, H. D., Dornbierer, D. A., Marten, L., Suay, D., Meling, D., Elsner, C., Wicki, I. A., Müller, J., Poetzsch, S. N., Caflisch, L., Hempe, A., Steinhart, C. P., Puchkov, M., Kost, J., Landolt, H. P., Seifritz, E., Quednow, B. B., & Scheidegger, M. (2024). Pharmacokinetics and pharmacodynamics of an innovative psychedelic N,N-dimethyltryptamine/harmine formulation in healthy participants: a randomized controlled trial. International Journal of Neuropsychopharmacology, 28(1). https://doi.org/10.1093/ijnp/pyaf001
Vancouver
Mueller MJ, Aicher HD, Dornbierer DA, Marten L, Suay D, Meling D, et al. Pharmacokinetics and pharmacodynamics of an innovative psychedelic N,N-dimethyltryptamine/harmine formulation in healthy participants: a randomized controlled trial. International Journal of Neuropsychopharmacology. 2024;28(1). doi:10.1093/ijnp/pyaf001
BibTeX
@article{Mueller2024,
author = {Mueller, Michael J and Aicher, Helena D and Dornbierer, Dario A and Marten, Laurenz and Suay, Dila and Meling, Daniel and Elsner, Claudius and Wicki, Ilhui A and Müller, Jovin and Poetzsch, Sandra N and Caflisch, Luzia and Hempe, Alexandra and Steinhart, Camilla P and Puchkov, Maxim and Kost, Jonas and Landolt, Hans-Peter and Seifritz, Erich and Quednow, Boris B and Scheidegger, Milan},
title = {Pharmacokinetics and pharmacodynamics of an innovative psychedelic N,N-dimethyltryptamine/harmine formulation in healthy participants: a randomized controlled trial},
journal = {International Journal of Neuropsychopharmacology},
year = {2024},
volume = {28},
number = {1},
doi = {10.1093/ijnp/pyaf001}
}
EUVIMED